Reply to S. Rossi et al and P. Palassin et al

Affiliation

• ¹ Abdul Rafeh Naqash, MD, Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK; Douglas B. Johnson, MD, Division of Medical Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN; Javid J. Moslehi, MD, Section of Cardio-Oncology & Immunology, Division of Cardiology and the Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA; and Elad Sharon, MD, MPH, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.